Ampersand, private investor buy out Australian biopharma firm
By Andrei Skvarsky.
Global health care private equity firm Ampersand Capital Partners and private investor Glenn Haifer have bought out Australian biopharmaceutical company Luina Bio, rebranding it as AcuraBio, according to a joint statement from Ampersand and AcuraBio.
Haifer is board chairman of AcuraBio. He is an Australian medical practitioner and entrepreneur.
The statement did not disclose what shares Ampersand and Haifer acquired in AcuraBio or how much they paid.
Ampersand, which is based in the United States, has more than $3bn of assets under management and is exclusively focused on growth-oriented investments in health care companies. It has offices in Boston and Amsterdam.
AcuraBio is a globally focused drug development and manufacturing company. It makes recombinant proteins and vaccines, and complex live biotherapeutic products.
The post Ampersand, private investor buy out Australian biopharma firm appeared first on EmergingMarkets.me.